Foresee Pharmaceuticals Completes Enrollment in Phase 3 Trial for CPP Treatment Foresee Pharmaceuticals has completed the enrollment for its Phase 3 Casppian trial, examining leuprolide mesylate's safety and efficacy in treating Central Precocious Puberty.

Foresee Pharmaceuticals Completes Enrollment in Phase 3 Trial for CPP Treatment #Taiwan #Taipei #Foresee_Pharmaceuticals #Casppian_trial #leuprolide_mesylate